The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21
Open accessAbstract
The fibroblast growth factor (FGF) 19 subfamily of ligands, FGF19, FGF21, and FGF23, function as hormones that regulate bile acid, fatty acid, glucose, and phosphate metabolism in target organs through activating FGF receptors (FGFR1-4). We demonstrated that Klotho and betaKlotho, homologous single-pass transmembrane proteins that bind to FGFRs, are required for metabolic activity of FGF23 and FGF21, respectively. Here we show that, like FGF21, FGF19 also requires betaKlotho. Both FGF19 and FGF21 can signal through FGFR1-3 bound by betaKlotho and increase glucose uptake in adipocytes expressing FGFR1. Additionally, both FGF19 and FGF21 bind to the betaKlotho-FGFR4 complex; however, only FGF19 signals efficiently through FGFR4. Accordingly, FGF19, but not FGF21, activates FGF signaling in hepatocytes that primarily express FGFR4 and reduces transcription of CYP7A1 that encodes the rate-limiting enzyme for bile acid synthesis. We conclude that the expression of betaKlotho, in combination with particular FGFR isoforms, determines the tissue-specific metabolic activities of FGF19 and FGF21.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“loss of KLB abolishes all effects of FGF21 in vitro and in vivo46,53–56.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“FGF21 elicits its biological effects by binding and activating a receptor complex composed of the co-receptor KLB and a traditional FGF receptor, fibroblast growth factor receptor 1c (FGFR1c)46,47.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“Interestingly, both FGF21 and another endocrine FGF, FGF15/19, share a requirement for KLB for signaling46,54, but what cross-talk, if any, exists between these signalling pathways in both physiological and pharmacological settings is unclear.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“FGF21 signals to a receptor complex comprised of FGF receptor 1c (FGFR1c) and its co-receptor β-klotho (KLB) [[143], [144], [145], [146]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [143]
In the citing paper
“Importantly, since FGF receptors are ubiquitously expressed, endocrine FGFs require a coreceptor to provide signaling specificity, which for FGF21 and FGF19 is the coreceptor β-klotho (71, 99, 140).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [71]
In the citing paper
“FGF21 functions in target tissues that express the traditional FGF receptor FGFR1c and the obligate coreceptor β-klotho (2, 27, 71, 99, 124, 140).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Self-citationFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Suppression of Aging in Mice by the Hormone Klotho
Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. (2005) · Science · doi:10.1126/science.1112766 · Cited by 1,935
Self-citationReceptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Self-citationKlotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,865
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Self-citationShimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,503
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K., Evans, W. E., O'Riordan, J., Speer, M., Econs, M., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,467
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–748 of 748
Genetic Disorders of Phosphate Homeostasis
White, K. E., Bringhurst, F. R., & Econs, M. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00062-7
Bayoumi, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Klotho-independent actions of FGF23—targets, signal transduction, and cellular effects
Musgrove, J., & Grabner, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818036-5.00001-x
Klotho—the discovery of the FGF23 coreceptor
Fukumoto, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818036-5.00022-7
Structural basis of FGF23 hormone signaling
Zinkle, A., Goetz, R. M., Chen, L., & Mohammadi, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818036-5.00002-1
Self-citationDevelopmental signaling pathways in adult energy homeostasis
Antonellis, P. J. (2021) · Figshare · doi:10.25394/pgs.15062292.v1
Wean, J. (2021) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2021.383
Jung, Y., Lee, K. W., Cho, J., Bae, D., Jeong, B., Jung, Y.-J., An, Y.-J., Kim, K., Lee, G., Kang, L.-W., et al. (2021) · bioRxiv · doi:10.1101/2021.11.16.468794
PPARs as Modulators of Cardiac Metabolism and Inflammation
Planavila, A., & van Bilsen, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800039-7.00011-6
Aging and Chronic Kidney Disease Viewed from the FGF-Klotho Endocrine System
Kuro‐o, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_14
Self-citationCorrelation between Fibroblast Growth Factor 23 and C-reactive Protein in Hemodialysis Patients
Ramezanzade, E., Nikfarjam, S., Namdar, M., & Nejatifar, F. (2022) · journal of ilam university of medical sciences · doi:10.52547/sjimu.30.1.65
Takebe, N., Hasegawa, Y., Matsushita, Y., Chiba, H., Onodera, K., Kinno, H., Oda, T., Nagasawa, K., Segawa, T., Takahashi, Y., et al. (2023) · Medicine · doi:10.1097/md.0000000000034797
Signaling pathway and pharmacology
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00005-6
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00000-7
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Бажан, Н. М., & En, M. (2023) · Успехи физиологических наук · doi:10.31857/s0301179823040033
Cardiokines and cardiac remodeling
Duttaroy, A. K., & Mallick, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99570-2.00014-x
Jakovleva, T., Kazantseva, A., Mamontova, K. Y., & Bazhan, N. (2024) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093024020315
Jakovleva, T., Kazantseva, A. Y., Mamontova, K. Y., & Бажан, Н. М. (2024) · Российский физиологический журнал им И М Сеченова · doi:10.31857/s0869813924040054
Schmidt, H. M., Tarling, E. J., & Vallim, T. Q. D. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2512733122
Insulin-sensitizing effects of fibroblast growth factor-21 in underfed sheep
dos Santos, A. C. R., McGuckin, M. M., Giesy, S. L., & Boisclair, Y. R. (2025) · Journal of Animal Science · doi:10.1093/jas/skaf217
Escuredo, G., & Miguel, J. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Kan, S., Pi, C., Zhang, L., Guo, D., Niu, Z., Liu, Y., Duan, M., Pu, X., Bai, M., Zhou, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22624717
Álvarez-Cienfuegos, A., Cantero-Nieto, L. M., García-Gómez, J. A., Callejas-Rubio, J. L., Martin, J., & Ortego-Centeno, N. (2021) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.17958d413e
The fibroblast growth factor-Klotho endocrine system in health and disease
Makoto, K.-O. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00034-7
Juber, M. C., King-McAlpin, S., Buscaglia, P., Sebag, J. A., & Potthoff, M. J. (2026) · Endocrinology · doi:10.1210/endocr/bqag040
Coopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire
Bedoya, J. U. (2021) · theses.fr (ABES) · doi:10.70675/d2df913bz04e7z457dzb21dzf6ae23303e0c
Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique
Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332
Xia, Q., Chen, Y., Shen, P., Gong, J., Lu, F.-E., & Chen, H. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121676
Hepatic Sirt2-PARP1-HMGB1 axis promotes exercise-mediated amelioration of MASH in mice
Li, S., Mu, W.-J., Zhao, Z.-A., Peng, W.-Q., Zhu, J., Li, R.-Y., Yan, L.-J., Li, Y., Luo, H.-Y., Chen, M., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3241-0
Zhao, S., Ji, Z., Wang, Y., Li, J., He, Y., Shen, J., Liu, C., Wang, L., Ma, X., Wang, S., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116260
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Calo, J., Ferreiro, D., Pérez-Tierra, G., Soengas, J. L., & Velasco, C. (2026) · Comparative biochemistry and physiology. Part A, Molecular & integrative physiology · doi:10.1016/j.cbpa.2026.112057
Adipokine in Metabolic Liver Disease: Adipo–Brain–Liver Cross talk
苏喻乐, Yang, Y., Sun, W., Yu, Z., Wang, Y., 刘世新, Chen, Z., Li, Y., Yang, X., Liu, J., et al. (2026) · International Journal of Endocrinology · doi:10.1155/ije/9009628
Advances in FGF/FGFR Signaling: Implications for Disease and Therapy
Song, M., Liu, X., Xiao, Y., Li, Y., & Zhao, H. (2026) · MedComm · doi:10.1002/mco2.70922
de Oliveira, T. H. C., & Gonçalves, G. K. N. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102568
Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917
Allosteric β-Klotho Modulation to Restore FGF21 Sensitivity in Type 2 DiabetesPreprint
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-10986278/v1
He, Z., Chen, P., Zhao, M., Song, W., Zhang, S., 雷秋香, Jie, X., & Chen, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1911556
Bile acid signaling in health and disease
Fan, Z., He, M., Liang, T., 张必利, Zhao, N., & Li, P. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00603-4
Taigade, S., Parab, S. B., & Doshi, G. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103390
Research Advances in the FGFR Signaling Axis in Hepatic Fibrosis
万, 良. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103343
Denora, M., Turi, A. D., Maqoud, F., Antonacci, M., Orlando, A., Drago, S., Malerba, E., Russo, F., & Tricarico, D. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119986
Gut microbiota and treatment response heterogeneity across pharmacological therapies for MASH
Yan, P., Cai, S., & Xia, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1968956
Liver-derived FGF21 contributes to protection against Alzheimer’s disease pathogenesis
Al‐Lahham, R., Dweik, Q., Murthy, S. G. S. S., Gill, S. K., Krishnan, B., Valdebenito, S., Eugenín, E. A., & Elferink, C. J. (2026) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2026-0020
Bai, L., Bai, D., Han, L., & Yang, Q. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.128
Bruss, M. D. (2011) · eScholarship (California Digital Library)
Metadata
- Authors
- Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- New York University (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 282
- Issue
- 37
- Pages
- 26687-26695
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2496965
- OpenAlex
- W2048411348
- Cited by
- 748
- References
- 35
- Citations by year
- 2026: 37 · 2025: 24 · 2024: 33 · 2023: 31 · 2022: 55 · 2021: 46 · 2020: 44 · 2019: 48 · 2018: 52 · 2017: 47 · 2016: 38 · 2015: 40 · 2014: 43 · 2013: 43 · 2012: 51
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Ellison Medical Foundation
- Welch Foundation
- Ted Nash Long Life Foundation
- Eisai
- National Institutes of Health (1r01ag015326-01, DK067158)
- National Institute on Aging (R01AG19712, R01AG025326, R01 AG 15326, R01AG019712)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-067158, R01DK067158)
- National Institute of Dental and Craniofacial Research (R01DE13686, R01DE013686)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- β-Klotho, Klotho, FGF19, FGF21, fibroblast growth factor 23, fibroblast growth factor receptor, FGFR4, FGFR1, tissue-specific signaling, bile acid metabolism, CYP7A1, hepatocytes, metabolic hormones
- MeSH terms
- Fibroblast Growth Factor-23, Klotho Proteins, Animals, Cholesterol 7-alpha-Hydroxylase, Fibroblast Growth Factors, Humans, Membrane Proteins, Organ Specificity, Phosphorylation, Signal Transduction, Adipocytes, Protein Isoforms, Hepatocytes, 3T3-L1 Cells, Extracellular Signal-Regulated MAP Kinases, Mice, Rats, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
